A groundbreaking therapy that encourages back pain patients to slowly take on movements they fear or that trigger pain, could relieve their suffering for at least three years, a study suggests.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results